Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
Year: 2025
Type: article
Language: en
Topic: Bacterial Infections and Vaccines
Authors and affiliations:
raw_author_name: Diane Gbesemete
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Maheshi N Ramasamy
raw_affiliation_strings: Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
raw_author_name: Muktar Ibrahim
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK
raw_author_name: Alison R Hill
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Lucy Raud
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Daniela M Ferreira
raw_affiliation_strings: Oxford Vaccine Group, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
raw_author_name: Jonathan Guy
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Adam P Dale
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Jay R Laver
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Tyween Coutinho
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
raw_author_name: Saul N Faust
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Science, University of Southampton, Southampton, UK
raw_author_name: Thomas A N Reed
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
raw_author_name: Gavin Babbage
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
raw_author_name: Lisa Weissfeld
raw_affiliation_strings: WCG Clinical, Princeton, NJ, USA
raw_author_name: Wei Lang
raw_affiliation_strings: WCG Clinical, Princeton, NJ, USA
raw_author_name: Camille Locht
raw_affiliation_strings: Institut Pasteur de Lille, Inserm U1019, CNRS UMR9017, Centre for Infection and Immunity of Lille, CHU Lille, Inserm, University of Lille, Lille, France. Electronic address: camille.locht@pasteur-lille.fr
raw_author_name: Vivek Samal
raw_affiliation_strings: ILiAD Biotechnologies, Weston, FL, USA
raw_author_name: Peter Goldstein
raw_affiliation_strings: ILiAD Biotechnologies, Weston, FL, USA
raw_author_name: Ken Solovay
raw_affiliation_strings: ILiAD Biotechnologies, Weston, FL, USA
raw_author_name: Keith Rubin
raw_affiliation_strings: ILiAD Biotechnologies, Weston, FL, USA
raw_author_name: Stephanie Noviello
raw_affiliation_strings: ILiAD Biotechnologies, Weston, FL, USA
raw_author_name: Robert C Read
raw_affiliation_strings: NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Controlled Human Infection Group, School of Clinical & Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK